Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company’s Proposed Generic to Xifaxan® for IBS-D

Alvogen, a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products, announced today a favorable district court ruling on multiple patents related to the companys proposed generic to Xifaxan, a treatment for irritable bowel syndrome with diarrhea (IBS-D) in adults.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, August 11, 2022
Information
Tags: 
Health, Pharmaceutical, Brand, IBS-D, Diarrhea, NASDAQ, Patient, Pharmaceutical industry, Alvogen
Geotags: 
NEW JERSEY, UNITED STATES, NORTH AMERICA
⚠ generated by AI ↴
Organisation: 
ALVOGEN
Summary
Key Points: 
  • Alvogen, a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products, announced today a favorable district court ruling on multiple patents related to the companys proposed generic to Xifaxan, a treatment for irritable bowel syndrome with diarrhea (IBS-D) in adults.
  • We are extremely pleased with the district courts decision, which brings us one step closer to bringing a more affordable alternative to patients taking Xifaxan for IBS-D, said Robert Wessman, Chairman of Alvogen.
  • Alvogen is a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products for the US market.
  • The company has a diverse portfolio and pipeline that includes both branded and generic products across various dosage forms.


Alvogen, a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products, announced today a favorable district court ruling on multiple patents related to the company’s proposed generic to Xifaxan®, a treatment for irritable bowel syndrome with diarrhea (IBS-D) in adults.

“We are extremely pleased with the district court’s decision, which brings us one step closer to bringing a more affordable alternative to patients taking Xifaxan for IBS-D,” said Robert Wessman, Chairman of Alvogen.

Mr. Wessman is also the founder and serves as Executive Chairman of Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide.

About Alvogen

Alvogen is a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products for the US market. The company has a diverse portfolio and pipeline that includes both branded and generic products across various dosage forms. The Alvogen-family of companies and include Alvogen US (Generics), Almatica (Brands) and Almaject (Injectables).

Copyright: 
Copyright Business Wire 2022